These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23640345)

  • 21. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
    Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vandetanib: a guide to its use in advanced medullary thyroid cancer.
    Keating GM; Lyseng-Williamson KA; Frampton JE
    BioDrugs; 2012 Dec; 26(6):431-5. PubMed ID: 22938056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vandetanib: first global approval.
    Commander H; Whiteside G; Perry C
    Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vandetanib for the treatment of thyroid cancer.
    Langmuir PB; Yver A
    Clin Pharmacol Ther; 2012 Jan; 91(1):71-80. PubMed ID: 22158569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
    Hsu C; Yang TS; Huo TI; Hsieh RK; Yu CW; Hwang WS; Hsieh TY; Huang WT; Chao Y; Meng R; Cheng AL
    J Hepatol; 2012 May; 56(5):1097-1103. PubMed ID: 22245891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vandetanib: too dangerous in medullary thyroid cancer.
    Prescrire Int; 2012 Oct; 21(131):233. PubMed ID: 23185843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
    Brose MS; Capdevila J; Elisei R; Bastholt L; Führer-Sakel D; Leboulleux S; Sugitani I; Taylor MH; Wang Z; Wirth LJ; Worden FP; Bernard J; Caferra P; Colzani RM; Liu S; Schlumberger M
    Endocr Relat Cancer; 2024 Aug; 31(8):. PubMed ID: 38828895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.
    Almeida MQ; Hoff AO
    Curr Opin Oncol; 2012 May; 24(3):229-34. PubMed ID: 22343387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
    Hu MI; Elisei R; Dedecjus M; Popovtzer A; Druce M; Kapiteijn E; Pacini F; Locati L; Krajewska J; Weiss R; Gagel RF
    Endocr Relat Cancer; 2019 Feb; 26(2):241-250. PubMed ID: 30557850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
    Wang SX; Zhang XW; Wang XX; An CM; Zhang YB; Liu W; Zhao YF; He XH; Li ZJ; Niu LJ; Tang PZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun; 54(6):439-444. PubMed ID: 31262109
    [No Abstract]   [Full Text] [Related]  

  • 35. Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
    Durante C; Paciaroni A; Plasmati K; Trulli F; Filetti S
    Endocrine; 2013 Oct; 44(2):334-42. PubMed ID: 23584948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Zhang X; Qin Y; Li H; Bai C; Zhu T; Xu J; Wu C; Wu M; Wang C; Song H; Wei L; He J
    Asian Pac J Cancer Prev; 2011; 12(11):2857-63. PubMed ID: 22393954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
    Yin Y; Qiu XY; Zhang YH; Zhang B
    Medicine (Baltimore); 2019 Aug; 98(31):e16392. PubMed ID: 31374006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
    Grande E; Kreissl MC; Filetti S; Newbold K; Reinisch W; Robert C; Schlumberger M; Tolstrup LK; Zamorano JL; Capdevila J
    Adv Ther; 2013 Nov; 30(11):945-66. PubMed ID: 24249433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.
    Starenki D; Park JI
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1529-40. PubMed ID: 23509102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vandetanib.
    Al-Ghusn AI; Bakheit AH; Attwa MW; AlRabiah H
    Profiles Drug Subst Excip Relat Methodol; 2023; 48():109-134. PubMed ID: 37061272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.